Thalidomide and turmeric team up to kill blood cancer cells
In research published in Organic & Biomolecular Chemistry, the spice-drug hybrid is shown to cause cell death in multiple myeloma, the second most common type of blood cancer.
Thalidomide was introduced in the 1950s to treat morning sickness in pregnant women, but was then banned because of its link to birth defects. The drug has recently been ‘rediscovered’ and approved for the effective treatment of multiple myeloma. It works by disturbing the microenvironment of tumour cells in bone marrow and modulating the immune system, but it breaks down in the body, causing side effects such as thrombosis.
Turmeric is a spice commonly used in South Asian and Middle Eastern cooking. Curcumin, a pigment in turmeric that gives it its characteristic yellow colour, has also been shown to have activity against cancer, including myeloma, but it has limited solubility in water so it isn’t easily taken up by the body.
The scientists have taken these two components and created a hybrid scaffold that combines structural features of the two. Analogues of this scaffold that have shown enhanced solubility and higher toxicity to myeloma cells than either thalidomide or curcumin, or a mixture of the two.
Most read news
Original publication
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.